Navid Khan

509 total citations
6 papers, 280 citations indexed

About

Navid Khan is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Infectious Diseases. According to data from OpenAlex, Navid Khan has authored 6 papers receiving a total of 280 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 2 papers in Cardiology and Cardiovascular Medicine and 1 paper in Infectious Diseases. Recurrent topics in Navid Khan's work include Muscle Physiology and Disorders (4 papers), RNA Interference and Gene Delivery (2 papers) and Cardiomyopathy and Myosin Studies (2 papers). Navid Khan is often cited by papers focused on Muscle Physiology and Disorders (4 papers), RNA Interference and Gene Delivery (2 papers) and Cardiomyopathy and Myosin Studies (2 papers). Navid Khan collaborates with scholars based in United States, Italy and Belgium. Navid Khan's co-authors include Craig M. McDonald, Jerry R. Mendell, Linda Lowes, Helen Eliopoulos, Rachael A. Potter, Louise R. Rodino‐Klapac, Jerry R. Mendell, Eugenio Mercuri, Damon R. Asher and Nathalie Goemans and has published in prestigious journals such as Journal of Chromatography A, Expert Opinion on Biological Therapy and Biotechnology and Applied Biochemistry.

In The Last Decade

Navid Khan

6 papers receiving 270 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Navid Khan United States	6	254	68	55	47	45	6	280
Florian Barthélémy United States	11	356 1.4×	98 1.4×	60 1.1×	52 1.1×	36 0.8×	24	447
Alexander P. Murphy United Kingdom	7	174 0.7×	41 0.6×	64 1.2×	37 0.8×	16 0.4×	14	213
Chao-Jen Wong United States	9	520 2.0×	46 0.7×	86 1.6×	57 1.2×	23 0.5×	11	541
Aaron S. Zelikovich United States	5	166 0.7×	16 0.2×	20 0.4×	75 1.6×	24 0.5×	8	265
Natalie F. Reash United States	7	214 0.8×	83 1.2×	46 0.8×	153 3.3×	28 0.6×	20	314
Alec M. DeSimone United States	8	283 1.1×	29 0.4×	42 0.8×	43 0.9×	20 0.4×	11	307
Kirsten E. Coleman United States	10	211 0.8×	184 2.7×	39 0.7×	34 0.7×	12 0.3×	14	333
Rita Perlingeiro United States	6	373 1.5×	51 0.8×	54 1.0×	66 1.4×	12 0.3×	8	383
John F. Harper United States	7	255 1.0×	94 1.4×	72 1.3×	64 1.4×	10 0.2×	11	332
Louise Deschênes Canada	5	298 1.2×	40 0.6×	16 0.3×	117 2.5×	39 0.9×	10	356

Countries citing papers authored by Navid Khan

Since Specialization

Citations

This map shows the geographic impact of Navid Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Navid Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Navid Khan more than expected).

Fields of papers citing papers by Navid Khan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Navid Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Navid Khan. The network helps show where Navid Khan may publish in the future.

Co-authorship network of co-authors of Navid Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Navid Khan. A scholar is included among the top collaborators of Navid Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Navid Khan. Navid Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

McDonald, Craig M., Perry B. Shieh, Hoda Abdel‐Hamid, et al.. (2021). Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. Journal of Neuromuscular Diseases. 8(6). 989–1001. 72 indexed citations

2.

Mendell, Jerry R., Navid Khan, Helen Eliopoulos, et al.. (2021). Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls. Journal of Neuromuscular Diseases. 8(4). 469–479. 27 indexed citations

3.

Asher, Damon R., et al.. (2020). Clinical development on the frontier: gene therapy for duchenne muscular dystrophy. Expert Opinion on Biological Therapy. 20(3). 263–274. 59 indexed citations

4.

Khan, Navid, Helen Eliopoulos, Lixin Han, et al.. (2019). Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases. 6(2). 213–225. 67 indexed citations

5.

Khan, Navid, et al.. (2011). A novel primary amine-based anion exchange membrane adsorber. Journal of Chromatography A. 1218(32). 5386–5392. 32 indexed citations

6.

Khan, Navid, et al.. (2008). Filter preconditioning enables representative scaled‐down modelling of filter capacity and viral clearance by mitigating the impact of virus spike impurities. Biotechnology and Applied Biochemistry. 52(4). 293–301. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact